Recent submissions

Imaging Response to Contemporary Immuno-oncology Combination Therapies in Patients With Metastatic Renal Cell Carcinoma

Ernst, Matthew; Yuasa, Takeshi; Takemura, Kosuke; Suárez Rodríguez, Cristina; Navani, Vishal; Wells, Connor; Donskov, Frede (Publication date: 2022-09-09)

Combination Therapies; Metastatic Renal Cell Carcinoma

ESMO Precision Oncology Working Group recommendations on the structure and quality indicators for molecular tumour boards in clinical practice

Boscolo Bielo , Luca; Aftimos, Philippe; Beltran, Himisha; Benary, Manuela; Westphalen, Benedikt; Chakravarty, Debyani; Dienstmann, Rodrigo; Mateo, Joaquin (Publication date: 2025-10-16)

Molecular tumour boards; Precision medicine; Precision oncology

Rapid mechanical phenotyping of breast cancer cells based on stochastic intracellular fluctuations

Cano, Álvaro; L. Yubero, Marina P.; Millá, Carmen; Puerto-Belda, Verónica; Ruz Martinez, Jose Jaime; M. Kosaka, Priscila; Malumbres, Marcos (Publication date: 2025-01-10)

Cancer; Cancer systems biology

SPIRIT-DEFINE explanation and elaboration: recommendations for enhancing quality and impact of early phase dose-finding clinical trials protocols

Ursino, Moreno; Dimairo, Munyaradzi; Solovyeva, Olga; Ashby, Deborah; Villacampa Javierre, Guillermo; Rekowski, Jan (Publication date: 2025-03-17)

Dose escalation/de-escalation; Dose-finding; Early phase trials

Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression

Napolitano, Stefania; Matrone, Nunzia; Muddassir, A. L.; Sorokin, A.; De Falco, Vincenzo; Martini, Giulia (Publication date: 2021-04-20)

Càncer colorectal; Resistència a inhibidors de MEK; Inhibidors de PD-L1

Mast cells impair melanoma cell homing and metastasis by inhibiting HMGA1 secretion

Benito Martin, Alberto; Nogues, Laura; Hergueta-Redondo, Marta; Castellano-Sanz, Elena; Garvin, Eduardo; Cioffi, Michele; Villanueva Cardús, Josep (Publication date: 2023-05-11)

Mast cells; Melanoma; Metastasis

The microproteome of cancer: from invisibility to relevance

Merino Valverde, Iñaki; Greco, Emanuela; Abad Mendez, Maria (Publication date: 2021-11-11)

Càncer; Micropèptid; Supressors de tumors

Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in advanced non-small cell lung cancer

Salifu, Idoko; Singh, Navneet; Berraondo, Maria; Remon, Jordi; Salifu, Stephanie; Severson, Eric; Quintana, Angela; Peiró, Sandra (Publication date: 2023-05-22)

Antibody-drug conjugates, Immune-checkpoint inhibitors; Non-small cell lung cancer

Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse

Bobillo Varela, Sabela; Joffe, Erel; Sermer, David; Mondello, Patrizia; Ghione, Paola; Caron, Philip C. (Publication date: 2022-02-25)

Limfoma de cèl·lules B; Supervivència lliure de malaltia

Genetic immune escape in cancer: timing and implications for treatment

Chowell, Diego; Martínez-Jiménez, Francisco (Publication date: 2025-04-22)

Immunotherapy resistance; Tumor evolution; Tumor microenvironment

Targeted multiplex proteomics for molecular prescreening and biomarker discovery in metastatic colorectal cancer

Garazi, Serna; Cecchi, Fabiola; Fasani, Roberta; Thyparambil, Sheeno; Elez Fernandez, Mª Elena; Vivancos Prellezo, Ana; Tabernero Caturla, Josep; Nuciforo, Paolo Giovanni; Landolfi, Stefania; Ruiz Pace, Fiorella; Jimenez, Jose; Dienstmann, Rodrigo (Publication date: 2020-07-08)

Biomarcadores del cáncer; Cáncer metástico colorrectal; Terapias experimentales

Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial

Schoffski, Patrick; Heinrich, Michael; Jones, Robin; George, Suzanne; Gelderblom, Hans; von Mehren, Margaret; Serrano, Cesar (Publication date: 2024-02-22)

Ripretinib; Gastrointestinal stromal tumor; Biomarker

Decoding protein methylation function with thermal stability analysis

Sayago, Cristina; Sánchez-Wandelmer, Jana; Garcia-Martinez, Fernando; Hurtado, Begoña; Lafarga, Vanesa; Prieto, Patricia (Publication date: 2023-06-19)

Methylation; Proteomics

Immunotherapies against HER2-Positive Breast Cancer

Román Alonso, Macarena; Arribas López, Joaquin Vicente; Duro Sánchez, Santiago (Publication date: 2023-03-20)

Immunotherapy; Resistance; Vaccines

Patritumab deruxtecan in leptomeningeal metastatic disease of solid tumors: the phase 2 TUXEDO-3 trial

Preusser, Matthias; Garde-Noguera, Javier; GARCIA MOSQUERA, JUAN JOSE; Gion, María; Greil, Richard; Arumí De Dios, Míriam (Publication date: 2025-09-16)

Patritumab deruxtecan; Leptomeningeal metastatic disease; Solid tumors

A phase I trial of LHC165 single agent and in combination with spartalizumab in patients with advanced solid malignancies

Jiménez, Miguel Martín; Shimizu, Toshio; Keam, Bhumsuk; Rutten, Annemie; Curigliano, Giuseppe; Meric-Bernstam, Funda; GARRALDA, Elena (Publication date: 2024-10-22)

Tumors sòlids avançats

First-in-human study of FAZ053, an anti-programmed death-ligand 1 (anti-PD-L1) monoclonal antibody, alone and in combination with spartalizumab (anti-PD-1), in patients with advanced malignancies

Tan, David; Martín Liberal, Juan Jesús; Geva, Ravit; Gucalp, Ayca; Janku, Filip; Takahashi, Shunji (Publication date: 2025-07-10)

Advanced alveolar soft part sarcoma; Chordoma; Spartalizumab

Articles científics - VHIO: Recent submissions

Imaging Response to Contemporary Immuno-oncology Combination Therapies in Patients With Metastatic Renal Cell Carcinoma

ESMO Precision Oncology Working Group recommendations on the structure and quality indicators for molecular tumour boards in clinical practice

Rapid mechanical phenotyping of breast cancer cells based on stochastic intracellular fluctuations

SPIRIT-DEFINE explanation and elaboration: recommendations for enhancing quality and impact of early phase dose-finding clinical trials protocols

Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression

Mast cells impair melanoma cell homing and metastasis by inhibiting HMGA1 secretion

The microproteome of cancer: from invisibility to relevance

Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in advanced non-small cell lung cancer

Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse

Genetic immune escape in cancer: timing and implications for treatment

Targeted multiplex proteomics for molecular prescreening and biomarker discovery in metastatic colorectal cancer

Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial

Decoding protein methylation function with thermal stability analysis

Immunotherapies against HER2-Positive Breast Cancer

Patritumab deruxtecan in leptomeningeal metastatic disease of solid tumors: the phase 2 TUXEDO-3 trial

A phase I trial of LHC165 single agent and in combination with spartalizumab in patients with advanced solid malignancies

First-in-human study of FAZ053, an anti-programmed death-ligand 1 (anti-PD-L1) monoclonal antibody, alone and in combination with spartalizumab (anti-PD-1), in patients with advanced malignancies

Association of radiation-induced normal tissue toxicity with a high genetic risk for rheumatoid arthritis

miR-203 drives breast cancer cell differentiation

Elevated levels of MMP12 sourced from macrophages are associated with poor prognosis in urothelial bladder cancer

Articles científics - VHIO: Recent submissions

Imaging Response to Contemporary Immuno-oncology Combination Therapies in Patients With Metastatic Renal Cell Carcinoma ﻿

ESMO Precision Oncology Working Group recommendations on the structure and quality indicators for molecular tumour boards in clinical practice ﻿

Rapid mechanical phenotyping of breast cancer cells based on stochastic intracellular fluctuations ﻿

SPIRIT-DEFINE explanation and elaboration: recommendations for enhancing quality and impact of early phase dose-finding clinical trials protocols ﻿

Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression ﻿

Mast cells impair melanoma cell homing and metastasis by inhibiting HMGA1 secretion ﻿

The microproteome of cancer: from invisibility to relevance ﻿

Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in advanced non-small cell lung cancer ﻿

Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse ﻿

Genetic immune escape in cancer: timing and implications for treatment ﻿

Targeted multiplex proteomics for molecular prescreening and biomarker discovery in metastatic colorectal cancer ﻿

Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial ﻿

Decoding protein methylation function with thermal stability analysis ﻿

Immunotherapies against HER2-Positive Breast Cancer ﻿

Patritumab deruxtecan in leptomeningeal metastatic disease of solid tumors: the phase 2 TUXEDO-3 trial ﻿

A phase I trial of LHC165 single agent and in combination with spartalizumab in patients with advanced solid malignancies ﻿

First-in-human study of FAZ053, an anti-programmed death-ligand 1 (anti-PD-L1) monoclonal antibody, alone and in combination with spartalizumab (anti-PD-1), in patients with advanced malignancies ﻿

Association of radiation-induced normal tissue toxicity with a high genetic risk for rheumatoid arthritis ﻿

miR-203 drives breast cancer cell differentiation ﻿

Elevated levels of MMP12 sourced from macrophages are associated with poor prognosis in urothelial bladder cancer ﻿

Imaging Response to Contemporary Immuno-oncology Combination Therapies in Patients With Metastatic Renal Cell Carcinoma

ESMO Precision Oncology Working Group recommendations on the structure and quality indicators for molecular tumour boards in clinical practice

Rapid mechanical phenotyping of breast cancer cells based on stochastic intracellular fluctuations

SPIRIT-DEFINE explanation and elaboration: recommendations for enhancing quality and impact of early phase dose-finding clinical trials protocols

Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression

Mast cells impair melanoma cell homing and metastasis by inhibiting HMGA1 secretion

The microproteome of cancer: from invisibility to relevance

Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in advanced non-small cell lung cancer

Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse

Genetic immune escape in cancer: timing and implications for treatment

Targeted multiplex proteomics for molecular prescreening and biomarker discovery in metastatic colorectal cancer

Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial

Decoding protein methylation function with thermal stability analysis

Immunotherapies against HER2-Positive Breast Cancer

Patritumab deruxtecan in leptomeningeal metastatic disease of solid tumors: the phase 2 TUXEDO-3 trial

A phase I trial of LHC165 single agent and in combination with spartalizumab in patients with advanced solid malignancies

First-in-human study of FAZ053, an anti-programmed death-ligand 1 (anti-PD-L1) monoclonal antibody, alone and in combination with spartalizumab (anti-PD-1), in patients with advanced malignancies

Association of radiation-induced normal tissue toxicity with a high genetic risk for rheumatoid arthritis

miR-203 drives breast cancer cell differentiation

Elevated levels of MMP12 sourced from macrophages are associated with poor prognosis in urothelial bladder cancer